DURHAM, NC, December 13, 2022 (Business Wire) – Tellus Therapeutics, a neonatal care company developing treatments for newborns in the neonatal intensive care unit (NICU), announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The capital will be used to continue important preclinical work conducted through the seed investment with the Xontogeny development team and to advance TT-20, the company’s lead candidate for the treatment of white matter brain injury in preterm infants, as well as the company’s pipeline programs.

November 10th, 2022 (Drug Discovery News) – A mammal’s first source of nutrients comes from milk. Filled with proteins, sugars, lipids, antibodies, cells, hormones and prebiotics, milk provides the necessary nourishment to help babies develop into healthy adults (1). But scientists have discovered that milk components are not just important for child development; they can have therapeutic effects too.

DURHAM, N.C, May 12, 2021 –(BUSINESS WIRE)– Tellus Therapeutics, Inc., a biopharmaceutical company developing TT-20 as a treatment for white matter injury (WMI) and myelin repair in premature babies, today announced a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling work.

DURHAM, NC, UNITED STATES, December 7, 2020 — Tellus Therapeutics today announced the award of a Phase 1 NINDS SBIR grant of $696,000 to fund further preclinical development of TT-20.

DURHAM, NORTH CAROLINA, October 21, 2020 — Tellus Therapeutics today announced that the U.S. FDA granted Orphan Drug and Rare Pediatric Drug designations for Neonatal Brain Injury Program TT-20.

DURHAM, NORTH CAROLINA, UNITED STATES, October 5, 2020 — Tellus Therapeutics today announced the appointment of Drs. Terrie Inder and Chi Hornik to the Scientific Advisory Board (SAB).